Ind-Swift Laboratories reported a strong financial performance for the first quarter of FY27, marked by sharp gains in profitability and margins.

 

For the quarter ended June 30, 2026, the company’s operating income rose 21.16% year-on-year to Rs. 186.08 crore, while operating EBITDA surged 2.85 times to Rs. 33.32 crore from Rs. 8.66 crore a year earlier.

 

Operating EBITDA margin expanded sharply to 17.91%, up 1,258 basis points year-on-year from 5.33%. Profit after tax, excluding exceptional items, more than doubled to Rs. 24.68 crore, compared with Rs. 8.12 crore in Q1 FY26. PAT margin also strengthened to 13.26%, an improvement of nearly 827 basis points.

 

The company said the quarter marked another step in its transformation from an API-focused business into a focused, debt-free finished dosage formulations (FDF) platform, backed by expanding international operations and growing presence across regulated and emerging markets.

 

A key growth catalyst during the quarter was the commercialisation of the CDMO partnership with Viatris in the US, Manx in the UK and Arrotex in Australia. The partnership is expected to generate an incremental Rs. 200-220 crore in revenue during FY27.

 

The company also commercialised two products during the quarter — Ibuprofen Sachet for the European market and Macrogol Sachet for the UK and Australian markets.

 

Ind-Swift Laboratories further strengthened its global product pipeline, with the number of dossiers filed increasing to more than 2,100 from over 1,915 previously. Product registrations also climbed to more than 900 from 750.

 

The company is simultaneously advancing the planned upgrade of its Samba manufacturing facility to EU-GMP and PIC/S standards. The upgrade is expected to expand export capabilities, facilitate filings in regulated markets and improve the company’s long-term growth prospects.

 

N.R. Munjal, Chairman of Ind-Swift Laboratories, said: “Q1 FY27 has been an excellent start to the year for Ind-Swift Laboratories, as we continue to build on our transformation from an API player into a focused FDF manufacturer."

 

"The Company delivered a strong quarter, with operating EBITDA improving 2.85x YoY to Rs.33.32 crore and op. EBITDA margin expanding by 1,258 bps YoY to 17.91%. PAT (excluding exceptional items) stood at Rs.24.68 crore, a 2.04x YoY jump, while PAT margin improved by 827 bps YoY to 13.26%."